Neoadjuvant treatment in stage III melanoma
Georgina Long shared on X:
“Another fantastic collaboration – Peter Mac Cancer Centre and Melanoma Institute Australia– neoadjuvant treatment stage III melanoma.
NeoTrio trial asked if BRAF-targeted therapy adds to immunotherapy. The path response rate higher with combo, but durability not there – watch for updates on this trial.”
Read further.
Source: Georgina Long/X
Georgina Long is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney, Australia. In recognition of her ground-breaking research and work, Professor Long was recognized with the Australian Academy of Health and Medical Sciences Outstanding Female Research Medal (2021) and was appointed as an Officer of the Order of Australia (2020). In February 2023 she was ranked the world’s 1st melanoma expert in all fields and disciplines. She is the Past President of the Society for Melanoma Research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023